LanreotideHormone TherapySafety Rating 8/10
Primary research areaAcromegaly
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range60-120 mg every 4 weeks deep SC
AdministrationSubcutaneous depot injection
Safety8/10 · FDA-approved (Somatuline)
NCAA D1Not listed
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Lanreotide
Mechanism of action
Long-acting somatostatin analog SSTR2/SSTR5 agonism suppressing GH and tumor growth
Safety profile
Injection site reactions, GI effects, cholelithiasis, bradycardia · Approved for acromegaly/NETs; GI side effects; gallstones; well-characterized
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Lanreotide below your target.
Related pages